Gilead and Arcus expand partnership, adding inflammation targets

Gilead and Arcus are expanding their already significant partnership, adding inflammation targets to what was already one of the biggest collaboration deals in the biotech world. In 2020, the companies announced a 10-year agreement to go after cancer targets that came with a $175 million upfront, a $200 million equity…

...

Click to view original post